Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343322 | 1.00 | MAPK1 (0.35) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL4818612 | 1.00 | MAPK1 (0.35) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL14596578 | 0.95 | KMT2A (0.37) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL4821470 | 0.91 | ALDH1A1 (0.33) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL14582398 | 0.91 | ALDH1A1 (0.33) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL23925419 | 0.91 | ALDH1A1 (0.33) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL23925421 | 0.91 | ALDH1A1 (0.33) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL977522 | 0.91 | MAPK1 (0.35) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL3117730 | 0.91 | MAPK1 (0.35) | MAPK1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL80486 | 0.91 | MAPK1 (0.35) | MAPK1KMT2AMEN1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149455-A1 | Use of Triazolopyrimidines for Controlling Plant Diseases on Legumes | BAYER CROPSCIENCE AG (DE) | 2009-06-11 | — | — | US | claimed |
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | claimed |
| US-6699855-B2 | PYRROLOPYRAZINONES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-02 | — | — | US | claimed |
| US-6699874-B2 | SURFACE ACTIVE AGENT AND SYNERGISTICALLY EFFECTIVE AMOUNTS OFAN AZOLOPYRIMIDINE | BASF AKTIENGESELLSCHAFT (DE) | 2004-03-02 | — | — | US | claimed |
| US-6656944-B2 | Synergistc mixtures | BASF AKTIENGESELLSCHAFT (DE) | 2003-12-02 | — | — | US | claimed |
| US-20030206968-A1 | Fungicidal mixtures | COTTER HENRY VAN TUYL (US) | 2003-11-06 | — | — | US | claimed |
| EP-1307200-A2 | SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | Wyeth (US) | 2003-05-07 | — | — | EP | claimed |
| US-6518275-B1 | Fungicidal mixtures | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-11 | — | — | US | claimed |
| US-20020111380-A1 | Fungicidal mixtures | BASF AKTIENGESELLSCHAFT (DE) | 2002-08-15 | — | — | US | claimed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | claimed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | claimed |
| US-20020045631-A1 | Enhancement of the efficacy of triazolopyrimidines | INTELLECTUAL PROPERTY DEPARTMENT, BASF AKTIENGESELLSCHAFT (DE) | 2002-04-18 | — | — | US | claimed |
| WO-2002002563-A2 | SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH (US) | 2002-01-10 | — | — | WO | claimed |
| US-6277856-B1 | SYNERGISTIC MIXTURE COMPRISING AN AZOLOPYRIMIDINE DERIVATIVE AND A SYNTHETIC STROBILURINE DERIVATIVE IN A CARRIER TO CONTROL GROWTH OF PHYTOPATHOGENIC FUNGI | AMERICAN CYNAMID CO. | 2001-08-21 | — | — | US | claimed |
| US-6268371-B1 | Fungicidal mixtures | AMERICAN CYANAMID CO. | 2001-07-31 | — | — | US | claimed |
| EP-0988790-A1 | Fungicidal mixtures | American Cyanamid Company (US) | 2000-03-29 | — | — | EP | claimed |
| EP-4653442-A1 | POLYCYCLIC COMPOUND FOR TREATING NEUROLOGICAL DISEASES AND TUMORS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024153202-A1 | POLYCYCLIC COMPOUND FOR TREATING NEUROLOGICAL DISEASES AND TUMORS | 中国科学院上海有机化学研究所 | 2024-07-25 | — | — | WO | disclosed |
| EP-0988790-A1 | Fungicidal mixtures | American Cyanamid Company (US) | 2000-03-29 | — | — | EP | disclosed |
| EP-0943241-A1 | Enhancement of the efficacy of triazolopyrimidines | American Cyanamid Company (US) | 1999-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030206968-A1 | Fungicidal mixtures | DDT, TPMT, CYP2D6 | MAPK1 3124/4885KMT2A 2128/4885MEN1 196/4885 |
| US-20020111380-A1 | Fungicidal mixtures | TYR, MAOA, PMM2 | MAPK1 2595/4885KMT2A 522/4885MEN1 599/4885 |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | MAPK1 1202/4885KMT2A 3703/4885MEN1 3394/4885 |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | TUBB3, TUBA1C, TUBB1 | MAPK1 916/4885KMT2A 2012/4885MEN1 2807/4885 |
| US-20090149455-A1 | Use of Triazolopyrimidines for Controlling Plant Diseases on Legumes | TYMP, CCNT2, PNPO | MAPK1 1694/4885KMT2A 1970/4885MEN1 4431/4885 |
| US-20020045631-A1 | Enhancement of the efficacy of triazolopyrimidines | EPX, CYP2E1, PTPN3 | MAPK1 2299/4885KMT2A 3027/4885MEN1 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.